KR910009663A - 피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법 - Google Patents

피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법 Download PDF

Info

Publication number
KR910009663A
KR910009663A KR1019900017881A KR900017881A KR910009663A KR 910009663 A KR910009663 A KR 910009663A KR 1019900017881 A KR1019900017881 A KR 1019900017881A KR 900017881 A KR900017881 A KR 900017881A KR 910009663 A KR910009663 A KR 910009663A
Authority
KR
South Korea
Prior art keywords
pyridine
general formula
cyinoimino
compound
formula
Prior art date
Application number
KR1019900017881A
Other languages
English (en)
Inventor
도마니 기외르기
에제르 엘레머
쇤 이스트반
마튀즈 주디트
사기 카탈린
스즈포니 라스즐로
하조스 기외르기
레니에이 마르타
Original Assignee
가보르 게리브, 에바 프리드만
리히터 게데온 베기에스제티 기아르 알티.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가보르 게리브, 에바 프리드만, 리히터 게데온 베기에스제티 기아르 알티. filed Critical 가보르 게리브, 에바 프리드만
Publication of KR910009663A publication Critical patent/KR910009663A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식(Ⅰ)의 피리딘 유도체 :
    상기식에서, Q는 니트로 또는 시아노기이고; X1및 X2는 서로 독립적으로 수소 또는 할로겐원자 또는 트리플루오로메틸, 저급알킬 또는 알콕시기이거나, 또는 페닐고리의 탄소원자들중 어느 하나에 결합된 니트로기이다.
  2. 1-벤질-2-(니트로이미노)피리딘, 1-(2-플루오로벤질)-2-(니트로이미노)피리딘, 1-(2-클로로벤질)-2-(니트로아미노)피리딘, 1-(4-브로모벤질)-2-(니트로아미노)피리딘,1-(4-니트로벤질)-2-(니트로아미노)피리딘, 1-벤질-2-(시이노이미노)피리딘, 2-(시이노이미노)-1-(2-플루오로벤질)피리딘, 1-(2-클로로벤질)-2-(시이노이미노)피리딘, 1-(3-클로로벤질)-2-(시이노이미노)피리딘, 2-(시이노이미노)-1-(3-매톡시벤질)피리딘, 2-(시이노이미노)-1-(3-트리폴루오로메틸벤질)피리딘, 2-(시이노이미노)-1-(2-메틸벤질)피리딘, 2-(시이노이미노)-1-(4-메틸벤질)피리딘, 2-(시이노이미노)-1-(4-플루오로벤질)피리딘, 1-(4-클로로벤질)-2-(시이노이미노)피리딘, 1-(4-브로모벤질)-2-(시이노이미노)피리딘, 2-(시이노이미노)-1-(2-니트로벤질)피리딘. 2-(시이노이미노)-1-(4-니트로벤질)피리딘 및 2-(시이노이미노)-1-(2,6-디클로벤질)피리딘들로 이루어진 그룹으로부터 선택된 화합물.
  3. 활성 성분으로서 Q, X1및 X2가 제1항에 기재된 바와 같은 하나 이상의 일반식(Ⅰ)의 피리딘 유도체를 담체 및/또는 약리학적으로 통상 사용된 첨가제와의 화합물로서 포함하는 약리학적 조성물.
  4. a) 하기 일반식(Ⅲ)의 2-(치환아미노)피리딘 유도체를 유기 또는 무기염기의 존재하에서 하기 일반식(Ⅳ)의 벤질 할로겐화물과 반응시킨다음, 부산물로서 형성돈 하기 일반식(Ⅴ)의 이성질체성 피리딘유도체로 부터 수득한 일반식(Ⅰ)의 피리딘 유도체를 분리하거나, 또는 b) 하기 일반식(Ⅳ)의 피리디늄염을 알칼리 처리하여 직접 제조할 수 있는 하기 일반식(Ⅱ)의 2-이미노피리딘유도체와 시안브롬화물을 반응시켜 X1및 X2는 하기와 같고 Q는 시아노기인 하기 일반식(Ⅰ)의 피리딘 유도체를 수득하는 것으로 이루어진, 하기 일반식(Ⅰ)의 피리딘 유도체의 제조방법:
    상기식에서, Q는 니트로 또는 시이노기이고; X1및 X2는 서로 독립적으로 수소 또는 할로겐원자 또는 트리플루오로메틸, 저급알킬 또는 알콕시기이거나 또는 페닐고리의 탄소원자들중 어느 하나에 결합된 니트로기이고; W는 염소 또는 브롬원자이고, Y는 할로겐이온이다.
  5. X1및 X2는 일반식(Ⅰ)에 대해 제4항에 기재된 바와같고, W는 브롬원자인 일반식(Ⅳ)의 벤질 할로겐화물을 사용하는 것을 특징으로 하는 제4항의 a)에 따른 방법.
  6. 유기염기의 존재 하에서 Q, X1및 X2는 일반식(Ⅰ)에 기재된 바와 같고, W는 일반식(Ⅳ)에 기재된 바와같은, 일반식(Ⅲ)의 화합물과 일반식(Ⅳ)의 화합물을 반응시키는 것을 특징으로 하는 제4항의 a)에 따른 방법.
  7. 제6항에 있어서, 유기염기로서 트리(지급알킬)아민을 사용하는 것을 특징으로 하는 방법.
  8. 무기염기의 존재하에서, Q, X1및 X2는 일반식(Ⅰ)에 기재된 바와 같고 W는 일반식(Ⅳ)에 기재된 바와같은, 일반식(Ⅲ)의 화합물과 일반식(Ⅳ)의 화합물을 반응시키는 것을 특징으로 하는 제4항의 a)에 따른 방법.
  9. 제8항에 있어서,무기염기로서 알칼리금속 탄산염을 사용하는 것을 특징으로 하는 방법.
  10. 양극성 비양성자성 용매 중에서. Q, X1및 X2는 일반식(Ⅰ)에 기재된 바와 같고 W는 일반식(Ⅳ)에 기재된 바와같은, 일반식(Ⅲ)의 화합물을 일반식(Ⅳ)의 화합물을 반응시키는 것을 특징으로 하는 제4항의 a) 및 제5항 내지 9항중 어느 한항에 따른 방법.
  11. 제10항에 있어서, 양극성 비양성자성용매로서 아세토니트릴 또는 저급케톤을 사용하는 것을 특징으로 하는 방법.
  12. 에테르형태 용매 중에서, X1및 X2는 일반식(Ⅰ)에 기재된 바와 같은 일반식(Ⅱ)의 2-이미노피리딘 유도체와 시안 브롬화물을 반응시키는 것을 특징으로 하는 제4항의 b)에 따른 방법.
  13. 활성성분으로서 Q, X1및 X2가 제1항에 기재된 바와같은 하나 이상의 일반식(Ⅰ)의 피리딘유도체를 담체 및/또는 약리학적으로 통상 사용되는 첨가제와 혼합하고 이러한 혼합물을 약리학적 조성물로 형성시키는 것으로 이루어진, 약리학적 조성물의 제조방법.
  14. Q, X1및 X2가 제1항에 기재된 바와같은 치료학적으로 유효량의 일반식(Ⅰ)의 피리딘유도체를 그 자체로 또는 약리학적 조성물의 형태로서 치료하고자 하는 포유류(사람 포함)에 투여하는 것을 특징으로 하는, 위산분비 억제, 조직보호, 고통감소 및 가벼운 소염치료 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900017881A 1989-11-07 1990-11-06 피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법 KR910009663A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU895807A HU207047B (en) 1989-11-07 1989-11-07 Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
HU5907/89 1989-11-07

Publications (1)

Publication Number Publication Date
KR910009663A true KR910009663A (ko) 1991-06-28

Family

ID=10970765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900017881A KR910009663A (ko) 1989-11-07 1990-11-06 피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법

Country Status (20)

Country Link
US (1) US5155123A (ko)
EP (1) EP0427526B1 (ko)
JP (1) JPH03169862A (ko)
KR (1) KR910009663A (ko)
CN (1) CN1052305A (ko)
AR (1) AR248394A1 (ko)
AT (1) ATE109137T1 (ko)
AU (1) AU631261B2 (ko)
CA (1) CA2029222A1 (ko)
DE (1) DE69011046T2 (ko)
DK (1) DK0427526T3 (ko)
ES (1) ES2057441T3 (ko)
FI (1) FI905493A0 (ko)
HU (1) HU207047B (ko)
IL (1) IL96252A (ko)
IN (1) IN171700B (ko)
NO (1) NO177263C (ko)
NZ (1) NZ235984A (ko)
PH (1) PH27440A (ko)
ZA (1) ZA908889B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
CN101267808A (zh) 2005-09-23 2008-09-17 弗·哈夫曼-拉罗切有限公司 新型制剂
EP2628389A4 (en) * 2010-08-31 2014-01-01 Meiji Seika Pharma Co Ltd AGENT FOR COMBATING HARMFUL ORGANISMS
BR112014004268A8 (pt) * 2011-08-26 2023-01-17 Meiji Seika Pharma Co Ltd método para a produção de agente de controle de praga
US20210238176A1 (en) 2018-08-07 2021-08-05 Syngenta Crop Protection Ag Pesticidally-active bicyclic heteroaromatic compounds
AR117291A1 (es) 2018-12-14 2021-07-28 Syngenta Crop Protection Ag Compuestos heterocíclicos de cianamida con actividad pesticida
WO2020169526A1 (en) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Pesticidally-active cyanamide heterocyclic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201119A (en) * 1978-09-18 1986-02-25 Mcneilab, Inc. Diaza-cyclic derivatives of guanidine
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
JPH07121909B2 (ja) * 1986-09-10 1995-12-25 日本バイエルアグロケム株式会社 新規複素環式化合物及び殺虫剤

Also Published As

Publication number Publication date
NO177263C (no) 1995-08-16
IN171700B (ko) 1992-12-12
DE69011046D1 (de) 1994-09-01
AU6582390A (en) 1991-05-23
CA2029222A1 (en) 1991-05-08
JPH03169862A (ja) 1991-07-23
AU631261B2 (en) 1992-11-19
NZ235984A (en) 1992-08-26
ZA908889B (en) 1991-10-30
HU207047B (en) 1993-03-01
IL96252A (en) 1994-12-29
CN1052305A (zh) 1991-06-19
HU895807D0 (en) 1990-01-28
AR248394A1 (es) 1995-08-18
PH27440A (en) 1993-07-02
NO904822D0 (no) 1990-11-06
DE69011046T2 (de) 1994-11-24
EP0427526A1 (en) 1991-05-15
ES2057441T3 (es) 1994-10-16
FI905493A0 (fi) 1990-11-06
EP0427526B1 (en) 1994-07-27
US5155123A (en) 1992-10-13
NO904822L (no) 1991-05-08
ATE109137T1 (de) 1994-08-15
NO177263B (no) 1995-05-08
HUT55758A (en) 1991-06-28
DK0427526T3 (da) 1994-08-29
IL96252A0 (en) 1991-08-16

Similar Documents

Publication Publication Date Title
DE69329727D1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
EP0437103A3 (en) Substituted 5-(alkyl)carboxamide imidazoles
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
GB2069481B (en) Substituted imidazole derivatives
NO863202D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive polypeptid-derivater.
DE69613347T2 (de) Bizyklisch substituierte hexahydrobenz(e)isoindole mit alpha-1-adrenerg antagonistischer wirkung
HU907025D0 (en) Process for producing substituted n-(imidazolyl-alkyl)-alanine derivatives and pharmaceutical preparatives containing these compounds as active substance
KR910009663A (ko) 피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법
MX9707472A (es) Diaminas radiosensibilizadoras y sus preparaciones farmaceuticas.
CA2244777A1 (en) 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
KR850003893A (ko) 11-치환된 5h,11h-피롤로[2,1,-c][1,4]벤즈옥사제핀의 제조방법
PL341539A1 (en) Heterocyclic toxins of topoisomerases
KR880000461A (ko) 안드로스트-4-엔-3,17-디온 및 그의 제조방법
EP0168921A3 (en) Chemical compounds
ES8501763A1 (es) "procedimiento para la fabricacion de derivados de la tetrahidro-5.6.7.7. 4h-tieno (3, 2-c) piridinona-2
EP0860169A3 (en) Compositions for oral administration containing pyridazinone compounds
CA2671776A1 (en) Gal3 receptor antagonists for the treatment of depression
DE2818290A1 (de) Neue naphthyridine
FI822706A0 (fi) Foerfarande foer framstaellning av farmakologiskt aktiva heteroaryloxipropanolaminer
KR970042548A (ko) 이미다조 피리딘 유도체,이의 제조방법 및 이를 함유한 약제학적 조성물
EP0189080A3 (en) (1,2,4-oxadiazol-3-yl)-arylmethanones, a process for their preparation and their use as medicaments
DE3708484A1 (de) Neue 3-(3-cycloalkylpropyl)amino-1-benzazepin-2-on-1-alkansaeuren
JPH0788335B2 (ja) 新規な２−〔（２，６−ジクロロフエニル）アミノ〕フエニルアセトキシ酢酸誘導体
KR910000642A (ko) 인돌 유도체 및 이의 제조방법
DE3467297D1 (en) Benzobicyclononane amino derivatives with anticonvulsive properties

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid